Osteoarthritis in dogs: does firocoxib vs carprofen give better pain control and mobility? — POSSIBLE

In dogs with osteoarthritis, does firocoxib vs carprofen give better pain control and mobility?

Shelf #599 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE: On the one head-to-head trial, firocoxib and carprofen performed very similarly overall, with a small firocoxib advantage on lameness reduction and on owner-assessed improvement. In Pollmeier 2006 (PMID: 17056650; a double-blind, randomised, controlled, multicentre field study in 218 dogs with osteoarthritis, firocoxib chewable tablets 5 mg/kg/day vs carprofen tablets 4 mg/kg/day for 30 days), the veterinarians' overall assessment — based on lameness, pain on manipulation/palpation, range of motion and joint swelling — found 92.5 per cent of firocoxib-treated dogs and 92.4 per cent of carprofen-treated dogs had improved, an absolute difference of about 0.1 percentage points; the reduction in lameness was significantly greater in the firocoxib group (the abstract does not give the size of that difference), and owner evaluations found 96.2 per cent of firocoxib dogs vs 92.4 per cent of carprofen dogs had improved, an absolute difference of 3.8 percentage points, which was statistically significant. Design class (a) for this shelf: Pollmeier 2006 establishes randomisation AND double-blinding and answers this shelf's own comparison (firocoxib vs carprofen) in this shelf's own population (dogs with osteoarthritis) — it is not a pooled-class or neighbouring-question trial. The stamp is POSSIBLE, not higher, because the evidence is a single trial, its outcomes are subjective clinician and owner scores rather than objective gait analysis, the abstract does not report the per-arm denominators behind its percentages or the magnitude of the lameness difference, and there was no placebo arm, so the ~92 per cent improvement rates themselves cannot be credited to either drug over natural fluctuation or caregiver expectation. Tier C is not engaged: no mortality or survival claim is made anywhere on this shelf. Drafted Nov 10, 2026 (VetMed build, topic #599); figures from the abstract, fetched and verified at drafting (no PMC full text exists for this record — checked at drafting).

Pollmeier 2006: in a double-blind randomised trial in 218 osteoarthritic dogs, overall improvement was 92.5% on firocoxib vs 92.4% on carprofen, with lameness reduction significantly greater on firocoxib and owner-rated improvement 96.2% vs 92.4%

Double-blind, randomised, controlled, multicentre field study (record's own wording; publication types include Randomized Controlled Trial, Multicenter Study)

Who: Dogs: 218 dogs with osteoarthritis in a double-blind, randomised, controlled, multicentre field study, treated for 30 days with firocoxib chewable tablets (5 mg/kg/day) or carprofen tablets (4 mg/kg/day). Efficacy, tolerance and ease of administration were assessed by owners and attending veterinarians; the veterinarians' overall scores were based on lameness, pain on manipulation/palpation, range of motion and joint swelling. The abstract does not report how the 218 dogs split between the two arms.

Result: On the veterinarians' overall assessment at the end of treatment, 92.5 per cent of firocoxib-treated dogs and 92.4 per cent of carprofen-treated dogs had improved (absolute difference about 0.1 percentage points). The reduction in lameness in firocoxib-treated dogs was significantly greater than in carprofen-treated dogs (magnitude not given in the abstract). Owner evaluations found 96.2 per cent of firocoxib dogs vs 92.4 per cent of carprofen dogs had improved (absolute difference 3.8 percentage points), a statistically significant difference.

Watch out: This is a head-to-head trial with no placebo or untreated arm, so it compares the two drugs with each other and cannot show how much of the ~92 per cent improvement either drug caused. Outcomes are subjective veterinarian and owner scores, not force-plate or other objective mobility measures, and the 30-day horizon says nothing about longer-term control or safety. The abstract gives percentages without per-arm denominators and gives no size for the significantly greater lameness reduction, so no larger firocoxib advantage than the printed percentages may be quoted. Equine NSAID head-to-head figures (shelf #811) are a different species and are never imported here.

Pollmeier M, Toulemonde C, Fleishman C, Hanson PD. Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. Vet Rec. 2006;159(17):547-51. PMID: 17056650. Registry ID: none in the record. MeSH: 4-Butyrolactone/administration & dosage, analogs & derivatives*, therapeutic use · Animals · Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, therapeutic use* · Carbazoles/administration & dosage, therapeutic use* · Dog Diseases/drug therapy* · Dogs · Double-Blind Method · Female · Male · Osteoarthritis/drug therapy, veterinary* · Sulfones/administration & dosage, therapeutic use* · Tablets · Treatment Outcome

Synthesis: one class-(a) trial finds the two drugs near-identical overall, with a small, incompletely quantified firocoxib edge on lameness and owner scores — POSSIBLE

Synthesis

Who: Synthesis of the one carded record above (Pollmeier 2006, 218 dogs with osteoarthritis randomised double-blind to firocoxib vs carprofen for 30 days) and of the near-miss records documented in the result, fetched at drafting and deliberately not carded as claim-carriers.

Result: (1) Direct evidence: Pollmeier 2006 is the only record found at drafting that randomises dogs with osteoarthritis to firocoxib vs carprofen and measures pain/mobility outcomes; overall veterinarian-assessed improvement was 92.5% vs 92.4%, lameness reduction significantly favoured firocoxib (size unreported in the abstract), and owner-assessed improvement was 96.2% vs 92.4%. (2) Near-misses, not carded: Sanderson 2009 (PMID: 19346540) is a systematic review of canine osteoarthritis management that rated the comfort level for both drugs from the underlying literature — a review, not a head-to-head record, and its home is the review literature, not this shelf; Monteiro-Steagall 2013 (PMID: 23782347) is a systematic review of NSAID adverse effects, a safety question with its own home, and reports no firocoxib-vs-carprofen efficacy comparison. (3) Out-of-scope neighbours, not imported: glucosamine–chondroitin (shelf #513), intra-articular hyaluronan (shelf #666) and acupuncture (shelf #605) are different interventions; the equine NSAID head-to-head (shelf #811) is a different species. Design class (a): randomisation and double-blinding are established by the carded record for this shelf's own comparison and population. Stamp ceiling is POSSIBLE: a single trial, subjective outcomes, and an unquantified lameness difference.

Watch out: One-home check at drafting: none of PMIDs 17056650, 19346540 or 23782347 appears in any other pack on disk. Do not quote the 92.5% and 92.4% improvement rates as proof either drug works — without a placebo arm they are within-trial descriptions; the randomised claim is only the comparison between the two drugs, and on overall scores that comparison is essentially a tie.

Synthesis of Pollmeier M et al. PMID: 17056650; Sanderson RO et al. PMID: 19346540; Monteiro-Steagall BP et al. PMID: 23782347. Registry IDs as on the individual cards (none in the records).

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.